|Synergy Pharmaceuticals, Inc.|
420 Lexington Avenue
United States - Map
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase II clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
|Synergy Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 2; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Gary S. Jacob Ph.D.,
Chairman, Chief Exec. Officer and Pres
|Mr. Bernard F. Denoyer CPA, M.B.A.,
Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec.
|Dr. Kunwar Shailubhai Ph.D.,
Chief Scientific Officer
|Mr. Marino Garcia ,
Sr. VP of Corp. Devel.
|Dr. Laura Barrow Pharm. D.,
Sr. VP of Clinical Operations
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|